AR091310A1 - Antibioticos de peptidos lineales - Google Patents
Antibioticos de peptidos linealesInfo
- Publication number
- AR091310A1 AR091310A1 ARP130100482A AR091310A1 AR 091310 A1 AR091310 A1 AR 091310A1 AR P130100482 A ARP130100482 A AR P130100482A AR 091310 A1 AR091310 A1 AR 091310A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- alkyl
- independently
- formula
- ch2ch2c
- Prior art date
Links
- 239000003242 anti bacterial agent Substances 0.000 title 1
- 229940088710 antibiotic agent Drugs 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000003107 substituted aryl group Chemical group 0.000 abstract 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 3
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 abstract 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 150000002829 nitrogen Chemical class 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 108010087967 type I signal peptidase Proteins 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 230000003115 biocidal effect Effects 0.000 abstract 1
- 229910052796 boron Inorganic materials 0.000 abstract 1
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 abstract 1
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
- 125000005017 substituted alkenyl group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1021—Tetrapeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Compuestos antibacterianos que en algunas formas de realización tienen un amplio espectro de bioactividad. En otras formas de realización pueden vencer la resistencia conferida por mutaciones de un solo aminoácido en posiciones determinadas de Peptidasas Señal (SPasas) bacterianas y en otras formas de realización proveen una actividad antibiótica de mayor amplitud de espectro. También se proveen composiciones farmacéuticas y métodos de tratamiento en los que se usan los compuestos. Reivindicación 1: Un compuesto caracterizado porque tiene la estructura de fórmula (1) donde: R¹ se selecciona entre: los compuestos de fórmula (2) a (9); R², R⁴, R¹⁰, R¹¹, R¹², y R¹³ son en forma independiente entre sí -H, -CH₃, -CH(CH₃)₂, -C(CH₃)₃, -CH(CH₃)(CH₂CH₃), -CH₂CH(CH₃)₂, -CH₂OH, -CH(OH)(CH₃), -CH₂CF₃, -CH₂C(O)OH, -CH₂C(O)OR²⁵, -CH₂CH₂C(O)OH, -CH₂CH₂C(O)OR²⁵, -CH₂C(O)NH₂, -CH₂CH₂C(O)NH₂, -CH₂CH₂C(O)N(H)C(H)(CH₃)CO₂H, -CH₂CH₂C(O)N(H)C(H)(CO₂H)CH₂CO₂H, -CH₂NR²¹R²², -(CH₂)₂NR²¹R²², -(CH₂)₃NR²¹R²², -(CH₂)₄NR²¹R²², -(CH₂)₄N(R²⁵)₃, -(CH₂)₄N(H)C(O)(2,3-dihidroxibenceno), alquilo C₁₋₈ opcionalmente sustituido, heteroalquilo C₁₋₈ opcionalmente sustituido, cicloalquilo C₃₋₈ opcionalmente sustituido, -CH₂-cicloalquilo C₃₋₈ opcionalmente sustituido, heterocicloalquilo opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, o un resto de fórmula (10) a (14); R³ es metilo, etilo, isopropilo, o ciclopropilo; R⁵ es H, metilo, etilo, o -CH₂OH; o R⁵ y R²⁴ junto con el átomo de boro forman un anillo que contiene boro de 5 ó 6 miembros; R⁶ es -C(=O)H, -CH₂C(=O)H, -C(=O)NHCH₂C(=O)H, -C(=O)C(=O)N(R¹⁴)₂, -B(OR²³)(OR²⁴), o un resto de formula (15); o R⁵ y R⁶ junto con el átomo de carbono forman el resto de fórmula (16); Rˣ es H, alquilo C₁₋₆ opcionalmente sustituido, heteroalquilo C₁₋₆ opcionalmente sustituido, o cicloalquilo C₃₋₈ opcionalmente sustituido; o Rˣ y R² junto con el átomo de nitrógeno forman un anillo que contiene nitrógeno opcionalmente sustituido; Rʸ es H o metilo; o Rʸ y R⁵ junto con el átomo de nitrógeno forman un anillo que contiene nitrógeno opcionalmente sustituido; Rᶻ es -NR¹⁵R¹⁶, -CH₂-NR¹⁵R¹⁶, o -(CH₂)₂-NR¹⁵R¹⁶; R⁷ es arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, heterocicloalquilo opcionalmente sustituido, alquenilo opcionalmente sustituido, o una cadena alquilo lineal o ramificada de aproximadamente 1 - 22 átomos de carbono, que opcionalmente comprende dentro de la cadena alquilo o en el extremo de una cadena alquilo un arilo opcionalmente sustituido, un heteroarilo opcionalmente sustituido, un heterocicloalquilo opcionalmente sustituido, o un resto de fórmula (17) opcionalmente sustituido, donde Z es una unión, O, S, NH, CH₂, NHCH₂, o CºC; R⁸ es una unión, -O-, o -N(R¹⁷)-, arilo opcionalmente sustituido, o heteroarilo opcionalmente sustituido; R⁹ es -CH₂OH, -CH₂CH(CH₃)₂, o restos de fórmula (10), (11) y (14); R¹⁴, R¹⁵, y R¹⁶ son en forma independiente entre sí H, o alquilo C₁₋₄; R¹⁷ es H, metilo, etilo, isopropilo, o ciclopropilo; R¹⁸, R¹⁹, y R²⁰ son en forma independiente entre sí H, o metilo; cada R²¹ es en forma independiente H, o alquilo C₁₋₄; cada R²² es en forma independiente H, alquilo C₁₋₄, -C(=NH)(NH₂), o -CH(=NH); R²³ y R²⁴ son en forma independiente entre sí H, o alquilo C₁₋₄; o R²³ y R²⁴ junto con el átomo de boro forman un anillo que contiene boro de 5 ó 6 miembros opcionalmente sustituido; cada R²⁵ es en forma independiente alquilo C₁₋₆; R²⁶ es H, alquilo C₁₋₄, alcoxi C₁₋₄, -CH₂C(O)OR²⁵, o -OCH₂C(O)OR²⁵; n es 0 ó 1; p es 0 ó 1; y q es 0 ó 1; o una sal farmacéuticamente aceptable, solvato, o prodroga del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261599851P | 2012-02-16 | 2012-02-16 | |
| US201261730928P | 2012-11-28 | 2012-11-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR091310A1 true AR091310A1 (es) | 2015-01-28 |
Family
ID=48982724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130100482 AR091310A1 (es) | 2012-02-16 | 2013-02-15 | Antibioticos de peptidos lineales |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US8999922B2 (es) |
| EP (1) | EP2814807A4 (es) |
| JP (2) | JP2015509942A (es) |
| KR (1) | KR20140132367A (es) |
| CN (1) | CN104254518A (es) |
| AR (1) | AR091310A1 (es) |
| CA (1) | CA2864669A1 (es) |
| EA (1) | EA201491511A1 (es) |
| HK (1) | HK1205736A1 (es) |
| MX (1) | MX357561B (es) |
| TW (1) | TWI601746B (es) |
| WO (1) | WO2013123456A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104254518A (zh) | 2012-02-16 | 2014-12-31 | 阿奇克斯制药公司 | 线性肽抗生素 |
| KR20150132362A (ko) * | 2013-03-15 | 2015-11-25 | 에이다에레이타, 리미티드 파트너쉽 | Pcsk9의 소분자 조절물질 및 그것의 사용 방법 |
| EP3033352A4 (en) * | 2013-08-14 | 2017-04-19 | RQX Pharmaceuticals, Inc. | Linear peptide antibiotics |
| WO2016165019A1 (en) * | 2015-04-14 | 2016-10-20 | B-Organic Films Corp. | Antiviral and antibacteria agents based on quaternary ammonium compound complexed with boric acid and its derivatives |
| CN109563144B (zh) | 2016-06-01 | 2023-03-28 | 雅斯娜 | 化合物 |
| ES2971784T3 (es) | 2016-06-21 | 2024-06-07 | Orion Ophthalmology LLC | Derivados heterocíclicos de prolinamida |
| EP3472151A4 (en) | 2016-06-21 | 2020-03-04 | Orion Ophthalmology LLC | CARBOCYCLIC PROLINAMIDE DERIVATIVES |
| KR102042600B1 (ko) * | 2018-02-13 | 2019-11-08 | 전북대학교산학협력단 | 항산화 및 항염증 활성을 갖는 홍갯지렁이 유래 신규 펩타이드 및 이의 이용 |
| KR20210146979A (ko) * | 2019-04-02 | 2021-12-06 | 베나토알엑스 파마슈티컬스, 인크. | 경구 전달 베타-락타마제 억제제의 고체 형태 및 이의 용도 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4499082A (en) * | 1983-12-05 | 1985-02-12 | E. I. Du Pont De Nemours And Company | α-Aminoboronic acid peptides |
| SI0932617T1 (en) * | 1996-10-18 | 2002-06-30 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
| HU227742B1 (en) * | 1996-10-18 | 2012-02-28 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
| GB9623908D0 (en) * | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
| GB9902399D0 (en) | 1999-02-03 | 1999-03-24 | Smithkline Beecham Plc | Compounds |
| JP2003522153A (ja) * | 2000-02-10 | 2003-07-22 | インターミューン インコーポレイテッド | ブドウ球菌属ビルレンスの新規アミノ酸インヒビターおよびペプチドインヒビター |
| AR029851A1 (es) * | 2000-07-21 | 2003-07-16 | Dendreon Corp | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c |
| SV2003000617A (es) * | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| WO2002095007A2 (en) * | 2001-05-23 | 2002-11-28 | Dendreon San Diego Llc | Conjugates activated by cell surface proteases and therapeutic uses thereof |
| US7244815B2 (en) * | 2001-05-23 | 2007-07-17 | The Curators Of The University Of Missouri | Attachment and elaboration strategies for inverse peptide synthesis |
| KR101076018B1 (ko) * | 2003-01-08 | 2011-10-21 | 유니버시티 오브 워싱톤 | 항균제 |
| PE20050374A1 (es) * | 2003-09-05 | 2005-05-30 | Vertex Pharma | Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc |
| MX2012010381A (es) * | 2010-03-09 | 2012-11-23 | Merck Canada Inc | Lipoglicopeptidos en puente que potencian la actividad de antibacterianos de beta-lactama. |
| CN104254518A (zh) | 2012-02-16 | 2014-12-31 | 阿奇克斯制药公司 | 线性肽抗生素 |
-
2013
- 2013-02-15 CN CN201380020376.2A patent/CN104254518A/zh active Pending
- 2013-02-15 EP EP13749947.1A patent/EP2814807A4/en not_active Withdrawn
- 2013-02-15 WO PCT/US2013/026520 patent/WO2013123456A1/en not_active Ceased
- 2013-02-15 AR ARP130100482 patent/AR091310A1/es unknown
- 2013-02-15 HK HK15106179.3A patent/HK1205736A1/xx unknown
- 2013-02-15 JP JP2014557853A patent/JP2015509942A/ja active Pending
- 2013-02-15 EA EA201491511A patent/EA201491511A1/ru unknown
- 2013-02-15 US US13/769,130 patent/US8999922B2/en not_active Expired - Fee Related
- 2013-02-15 KR KR1020147025651A patent/KR20140132367A/ko not_active Ceased
- 2013-02-15 CA CA2864669A patent/CA2864669A1/en not_active Abandoned
- 2013-02-15 MX MX2014009899A patent/MX357561B/es active IP Right Grant
- 2013-02-18 TW TW102105674A patent/TWI601746B/zh not_active IP Right Cessation
-
2015
- 2015-02-25 US US14/631,762 patent/US9708368B2/en not_active Expired - Fee Related
-
2017
- 2017-06-09 US US15/618,337 patent/US20170275334A1/en not_active Abandoned
-
2018
- 2018-03-08 JP JP2018042357A patent/JP2018135334A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TWI601746B (zh) | 2017-10-11 |
| JP2018135334A (ja) | 2018-08-30 |
| MX2014009899A (es) | 2015-03-09 |
| MX357561B (es) | 2018-07-13 |
| EA201491511A1 (ru) | 2014-12-30 |
| US20170275334A1 (en) | 2017-09-28 |
| KR20140132367A (ko) | 2014-11-17 |
| EP2814807A4 (en) | 2015-10-07 |
| CA2864669A1 (en) | 2013-08-22 |
| HK1205736A1 (en) | 2015-12-24 |
| US9708368B2 (en) | 2017-07-18 |
| US20150166605A1 (en) | 2015-06-18 |
| JP2015509942A (ja) | 2015-04-02 |
| EP2814807A1 (en) | 2014-12-24 |
| WO2013123456A1 (en) | 2013-08-22 |
| US20130217619A1 (en) | 2013-08-22 |
| US8999922B2 (en) | 2015-04-07 |
| TW201341403A (zh) | 2013-10-16 |
| CN104254518A (zh) | 2014-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR091310A1 (es) | Antibioticos de peptidos lineales | |
| AR095326A1 (es) | Heterociclos tricíclicos como inhibidores de la proteína bet | |
| AR096287A1 (es) | Pirrolobenzodiacepinas y conjugados | |
| AR095426A1 (es) | Inhibidores tripeptídicos de la epoxicetona proteasa | |
| CY1119015T1 (el) | 4'-αζιδο-3'φθορο υποκατεστημενα νουκλεοζιδιου παραγωγα ως αναστολεις αντιγραφης hcv rna | |
| AR098492A1 (es) | Derivados de purina | |
| AR089796A1 (es) | COMPUESTOS b-LACTAMICOS SUSTITUIDOS CON AMIDINA, SU PREPARACION Y USO | |
| CY1119134T1 (el) | Υποδοχεις της νεπριλυσινης | |
| AR104513A1 (es) | Derivados de ciclohexano sustituidos con amidas como inhibidores de tnks1 y/o tnks2 | |
| AR099363A1 (es) | Pirrolo[2,3-d]pirimidinil, pirrolo[2,3-b]pirazinil y pirrolo[2,3-d]piridinil acrilamidas | |
| AR096330A1 (es) | Derivados del bipirazol como inhibidores jak | |
| ES2626555T3 (es) | Pyridone amides como moduladores de canales de sodio | |
| AR096837A1 (es) | Heterociclos tricíclicos como inhibidores de proteínas bet | |
| AR098136A1 (es) | Compuestos de heteroarilo como inhibidores de btk y usos de los mismos | |
| AR093404A1 (es) | Compuestos macrociclicos que modulan la actividad de los inhibidores de la apoptosis | |
| AR103252A1 (es) | Compuestos de quinazolina | |
| AR092349A1 (es) | Imidazotriazincarbonitrilos utiles como inhibidores de quinasa | |
| AR095192A1 (es) | Quinolina y quinazolinamidas como modulares de canales de sodio | |
| AR096461A1 (es) | Anticuerpos conjugados de fármacos | |
| EA201491967A1 (ru) | Производные имидазотиадиазола в качестве ингибиторов активируемых протеазой рецепторов 4 (par4) для лечения агрегации тромбоцитов | |
| AR088423A1 (es) | Ligadores p1 ciclicos como inhibidores del factor xia | |
| AR094313A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR089489A1 (es) | Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas | |
| CY1116439T1 (el) | Τριαζολοπυριδινες | |
| EA202090860A1 (ru) | Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |